Novel metabolic targets and markers
OwnerSteven M. Watkins, Rebecca A. Baillieinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides metabolic markers and targets, especially PEMT activity and metabolic markers and components associated therewith useful for diagnosing and treating various disease conditions.
Claims156
A method for regulating the level of a fatty acid in a system comprising regulating the phosphatidylethanolamine-N-methyltransferase (PEMT) activity in the system whereby regulating the level of a fatty acid in the system, wherein the fatty acid is selected from the group consisting of 16:0, 18:0, 16:1n7, 18:1n7, 18:2n6, 20:4n6, 20:5n3, 22:6n3, saturated fatty acids, polyunsaturated fatty acids, and highly unsaturated fatty acids.
A method for decreasing the level of a fatty acid in a system comprising decreasing the CDP-choline activity in the system whereby decreasing the level of a fatty acid in the system, wherein the fatty acid is selected from the group consisting of 16:0, 16:1n7, 18:2n6, and saturated fatty acids.
A method for increasing the PEMT activity in a subject comprising administering to the subject an effective amount of an agent selected from the group consisting of folic acid, vitamin B6, growth hormone, sex hormone, β-3 adrenergic receptor agonist, niacin, and S-adenosylmethionine.
A method for regulating a lipoprotein component ratio in a system comprising regulating the PEMT activity in the system whereby regulating the lipoprotein component ratio in the system, wherein the lipoprotein component ratio is selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine.
A method of regulating the density or size of a lipoprotein in a system comprising regulating a lipoprotein component ratio selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine in the system whereby regulating the density or size of a lipoprotein in the system.
A method for regulating the density or size of a lipoprotein in the system comprising regulating the PEMT activity in the system whereby regulating the density or size of a lipoprotein in the system.
A method of assessing the density of a lipoprotein in a system comprising determining a lipoprotein component ratio selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine in the system wherein the lipoprotein component ratio is inversely related to the density of the lipoprotein in the system.
A method of assessing the size of a lipoprotein in a system comprising determining a lipoprotein component ratio selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine in the system wherein the lipoprotein component ratio correlates with the size of the lipoprotein in the system
A method of assessing the density of a lipoprotein in a system comprising determining the PEMT activity in the system, wherein the PEMT activity is inversely related to the density of the lipoprotein in the system.
A method of assessing the size of a lipoprotein in a system comprising determining the PEMT activity in the system, wherein the PEMT activity correlates with the size of the lipoprotein in the system
A method of assessing the density of a lipoprotein in a system comprising determining the homocysteine level of the system, wherein the homocysteine level correlates with the density of the lipoprotein in the system.
A method of assessing the size of a lipoprotein in a system comprising determining the homocysteine level of the system, wherein the homocysteine level is inversely related to the size of the lipoprotein in the system.
A method for treating or preventing a cardiovascular condition comprising administering to a subject in need of such treatment an agent, wherein the agent regulates a lipoprotein component ratio selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, triacylglyceride to phosphatidylcholine, and S-adenosylmethionine to S-adenosylhomocysteine.
A method for treating or preventing a cardiovascular condition comprising administering to a subject in need of such treatment an agent, wherein the agent regulates the PEMT activity.
A method for treating or preventing a cardiovascular condition comprising administering to a subject in need of such treatment an effective amount of estrogen, folic acid, vitamin B6, growth hormone, sex hormone, β-3 adrenergic receptor agonist, niacin, and S-adenosylmethionine.
A method for treating or preventing a cardiovascular condition comprising administering to a subject in need of such treatment an effective amount of an agent, wherein the agent regulates the level of 22:6n3 or 20:4n6.
A method for assessing the susceptibility of a subject to a cardiovascular condition comprising determining a lipoprotein component ratio selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to phosphatidylcholine, triacylglyceride to phosphatidylcholine in the subject, wherein a lipoprotein component ratio that is higher than a normal lipoprotein component ratio is indicative of the susceptibility of the subject to the cardiovascular condition.
A method for assessing the susceptibility of a subject to a cardiovascular condition comprising determining the PEMT activity in the subject, wherein a PEMT activity that is lower than a normal PEMT activity is indicative of the susceptibility of the subject to the cardiovascular condition.
A method for treating or preventing a neurological condition in a subject comprising administering to the subject an effective amount of an agent, wherein the agent regulates the PEMT activity.
A method for treating or preventing a neurological condition in a subject comprising administering to the maternal host of the subject an effective amount of an agent, wherein the agent regulates the PEMT activity of the maternal host of the subject.
A method for treating or preventing a neurological condition in a subject comprising administering to the subject an effective amount of an agent selected from the group consisting of folic acid, vitamin B6, growth hormone, sex hormone, β-1 adrenergic receptor agonist, β-2 adrenergic receptor agonist, β-3 adrenergic receptor agonist, niacin, and S-adenosylmethionine.
A method for treating or preventing a neurological condition in a subject comprising administering to the maternal host of the subject an effective amount of an agent selected from the group consisting of folic acid, vitamin B6, growth hormone, sex hormone, β-1 adrenergic receptor agonist, β-2 adrenergic receptor agonist, β-3 adrenergic receptor agonist, niacin, and S-adenosylmethionine.
A method for assessing the susceptibility of a subject to the toxicity of an agent comprising determining the level of PEMT activity in the subject, wherein a level of PEMT activity that is lower than a normal PEMT activity is indicative of the susceptibility of the subject to the toxicity of the agent.
A method for assessing the susceptibility of a subject to the toxicity of an agent comprising determining the level of CDP-choline activity in the subject, wherein a level of CDP-choline activity that is lower than a normal CDP-choline activity is indicative of the susceptibility of the subject to the toxicity of the agent.
A method for assessing the susceptibility of a subject to a condition associated with infertility comprising determining the level of PEMT activity in the subject, wherein a lower than normal PEMT activity is indicative of the susceptibility of the subject to a condition associated with infertility.
A method for assessing the exposure of a subject to an agent in an environment comprising determining the level of PEMT activity in the subject, wherein a lower than normal PEMT activity is indicative of a higher than normal exposure of the subject to the agent in the environment and wherein the agent is associated with infertility or gender disorder.
A method for assessing a condition in a subject comprising determining the level of PEMT activity in a subject, wherein the level of PEMT activity corresponds to the level of a condition selected from the group consisting of growth hormone, thyroid activity, eicosanoid production, insulin, and insulin resistance in the subject.
A method for predicting the effectiveness of an agent for the treatment of a neoplasia comprising determining the level of PEMT activity in a subject in response to the agent, wherein a decrease in the PEMT activity in response to the agent is predictive of the effectiveness of the agent for the treatment of the neoplasia.
A method of increasing milk production in a subject comprising administering to a subject in need of such treatment an agent, wherein the agent increases PEMT activity and whereby increases milk production of the subject.
A method of increasing the lipid content of milk in a subject comprising administering to a subject in need of such treatment an agent, wherein the agent increases PEMT activity and whereby increases the lipid content of milk, wherein the lipid is 22:6n3 or 20:4n6.
A method of increasing the phospholipid content of milk in a subject comprising administering to a subject in need of such treatment an agent, wherein the agent increases PEMT activity and whereby increases the phospholipid content of milk.
A method of assessing the susceptibility of a subject to a developmental condition comprising determining the level of PEMT activity in the subject, wherein a lower than normal level of PEMT activity in the subject is indicative of susceptibility of the subject to a developmental condition selected from the group consisting of birth defects, congenital developmental conditions, Microcephaly and mental retardation of uncontrolled phenylketonuria (PKU).
A method of assessing the susceptibility of a subject to a developmental condition comprising determining the level of PEMT activity in the maternal host of the subject, wherein a lower than normal level of PEMT activity in the maternal host of the subject is indicative of susceptibility of the subject to a developmental condition selected from the group consisting of birth defects, congenital developmental conditions, Microcephaly and mental retardation of uncontrolled phenylketonuria (PKU).
A method of preventing a birth defect of a subject comprising administering to the maternal host of the subject an agent, wherein the agent increases PEMT activity, 22:6n3, or 20:4n6 in the maternal host of the subject.
A method for preventing or treating a birth defect of a subject comprising administering to the subject an agent, wherein the agent increases the level of PEMT activity, 22:6n3, or 20:4n6 in the subject.
A method of treating or preventing a condition associated with the PEMT activity in a subject comprising administering to the subject an effective amount of an agent, wherein the agent regulates PEMT activity and wherein the condition associated with the PEMT activity is selected from the group consisting of cirrhosis, skin disorders, neoplasia, infectious diseases, inflammatory diseases, bone density, eicosanoid production, osteoporosis, insulin sensitivity or resistance, diabetes, obesity, renal function loss, autoimmune diseases, and atopic diseases, lipid accumulation in liver, liver steatosis, complications associated with liver transplantation, growth hormone deficiency or overproduction, and thyroid hormone disorders.
Dependencies are inferred from the claim text.